|
Accelerated Approvals Should Be Backed by Randomized Trials
Drugmakers conducting postmarket clinical trials should be required to conduct randomized clinical trials, according to the FDA’s Oncologic Drugs Advisory Committee.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives